ABOS
Acumen Pharmaceuticals, Inc.Company Information
- Company Name
- Acumen Pharmaceuticals, Inc.
- CIK
- CIK0001576885
- Category
- Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
- Ticker: Exchange
- ABOS: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2836
- SIC Description
- Biological Products, (No Diagnostic Substances)
- Ticker
- ABOS
SEC filing data through
Insider Sentiment
- Last purchase
- 2023-07-21
- Last sale
- 2026-06-17
- Shares purchased (TTM)
- 0
- Shares sold (TTM)
- 140,755
Institutional Sentiment
- As of
- 2026-03-31
- Institutional shares owned
- 45,081,869
- Shares outstanding
- 63,219,289
- Ownership
- 71.31%
Earnings Market Reaction
- Filing date
- 2026-08-12
- Price on filing date
- —
- 1-month reaction
- 26.69%
- 3-month reaction
- Pending
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 59 | 52 | 54 | 47 | 37 | 30 | 36 | 33 | 68 | 47 | 67 | 95 | ||||||
| Marketable Securities Current | 51 | 77 | 63 | 80 | 107 | 119 | 136 | 167 | 193 | 206 | 177 | 121 | ||||||
| Prepaid Expense And Other Assets Current | 5 | 5 | 5 | 6 | 5 | 6 | 7 | 7 | 6 | 3 | 3 | 3 | ||||||
| Assets Current | 116 | 133 | 122 | 132 | 148 | 155 | 178 | 208 | 267 | 256 | 247 | 219 | ||||||
| Marketable Securities Noncurrent | - | - | 0 | 9 | 23 | 49 | 60 | 59 | 21 | 44 | 63 | 67 | ||||||
| Operating Lease Right Of Use Asset | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 | ||||||
| Restricted Cash Noncurrent | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | 0 | ||||||
| Property Plant And Equipment Net | - | - | - | - | - | - | - | 0 | 0 | 0 | - | 0 | ||||||
| Restricted Cash | - | - | 0 | - | - | - | 0 | - | - | - | 0 | - | ||||||
| Other Assets Noncurrent | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | ||||||
| Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization | - | - | - | - | - | - | - | - | - | - | 0 | - | ||||||
| Assets | 116 | 134 | 123 | 142 | 172 | 204 | 239 | 267 | 289 | 301 | 310 | 286 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable Current | 13 | 2 | 1 | 1 | 2 | 1 | 6 | 2 | 4 | 3 | 1 | 1 | ||||||
| Accrued Liabilities Current | 8 | 5 | 10 | 8 | 12 | 7 | 7 | 5 | 4 | 3 | 6 | 3 | ||||||
| Short Term Borrowings | 20 | 14 | 9 | 4 | - | - | 0 | - | - | - | - | - | ||||||
| Finance Lease Liability Current | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 1 | - | ||||||
| Operating Lease Liability Current | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 | ||||||
| Liabilities Current | 47 | 29 | 30 | 22 | 25 | 19 | 28 | 20 | 15 | 8 | 13 | 6 | ||||||
| Operating Lease Liability Noncurrent | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | - | ||||||
| Long Term Debt | 12 | 17 | 22 | 27 | 30 | 30 | 29 | 30 | 29 | 30 | 30 | - | ||||||
| Other Liabilities Noncurrent | - | - | 0 | 0 | 0 | 0 | 0 | - | - | - | 0 | - | ||||||
| Liabilities | 59 | 46 | 52 | 49 | 55 | 49 | 57 | 50 | 45 | 39 | 43 | 6 | ||||||
Stockholders Equity | ||||||||||||||||||
| Preferred Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital | 557 | 555 | 517 | 514 | 512 | 509 | 507 | 505 | 502 | 500 | 489 | 487 | ||||||
| Retained Earnings Accumulated Deficit | -500 | -467 | -446 | -421 | -395 | -354 | -325 | -288 | -258 | -238 | -223 | -206 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | -0 | 0 | 0 | 0 | 0 | 0 | -0 | 1 | -0 | -0 | 0 | -1 | ||||||
| Stockholders Equity | 57 | 87 | 70 | 93 | 117 | 156 | 182 | 217 | 244 | 262 | 267 | 280 | ||||||
| Liabilities And Stockholders Equity | 116 | 134 | 123 | 142 | 172 | 204 | 239 | 267 | 289 | 301 | 310 | 286 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Preferred Stock Shares Authorized | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | ||||||
| Preferred Stock Shares Issued | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Preferred Stock Shares Outstanding | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 300 | 300 | 300 | 300 | 300 | 300 | 300 | 300 | 300 | 300 | 300 | 300 | ||||||
| Common Stock Shares Issued | 72 | 72 | 61 | 61 | 61 | 61 | 60 | 60 | 60 | 60 | 58 | 58 | ||||||
| Shares Outstanding | 72 | 72 | 61 | 61 | 61 | 61 | 60 | 60 | 60 | 60 | 58 | 58 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialAcumen Pharmaceuticals, Inc. (ABOS) — SEC Financial Statements & Analysis
Acumen Pharmaceuticals, Inc. (ABOS) is a biological products, (no diagnostic substances) company, incorporated in DE. Acumen Pharmaceuticals, Inc. trades on Nasdaq as: ABOS. Acumen Pharmaceuticals, Inc. (ABOS)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-12. Based on that filing, Acumen Pharmaceuticals, Inc. carries a market cap of $192.91M, a P/E ratio of -1.84x, a P/B ratio of 3.37x, a P/S ratio of 25.77x, an enterprise value of $164.80M, and an EV/EBITDA multiple of -1.56x. On profitability, it posts an operating margin of -2846.87%, a net margin of -2555.03%, a Return on Equity (ROE) of -120.50%, a Return on Assets (ROA) of -72.97%, and a Return on Invested Capital (ROIC) of -151.60%. Per share, it reports EPS of $-1.45, diluted EPS of $-1.45, free cash flow per share of $-1.27, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of -100.00% year-over-year, net income growth of -23.14% year-over-year, and EPS growth of -35.56% year-over-year. On the balance sheet, it maintains a current ratio of 2.47x, a quick ratio of 2.35x, working capital of $68.67M, a debt-to-equity ratio of 1.03x, a debt ratio of 0.51, an interest coverage ratio of -24.41x, free cash flow of $-91.79M (TTM), and net debt of $-28.11M. Figures sourced from SEC EDGAR.
- Market Cap
- $192.91M
- P/E TTM
- -1.84x
- EPS TTM
- $-1.45
- P/B TTM
- 3.37x
- ROE TTM
- -120.50%
- ROA TTM
- -72.97%
- Debt To Equity
- 1.03x
- Free Cash Flow TTM
- $-91.79M
- Net Revenue TTM Growth 1Y
- -100.00%
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Acumen Pharmaceuticals, Inc. in?
Acumen Pharmaceuticals, Inc. (ABOS) operates in the Biological Products, (No Diagnostic Substances) industry.
What exchange does ABOS trade on?
Acumen Pharmaceuticals, Inc. (ABOS) trades on the Nasdaq.
Where is Acumen Pharmaceuticals, Inc. incorporated?
Acumen Pharmaceuticals, Inc. is incorporated in DE.
When was Acumen Pharmaceuticals, Inc. (ABOS)'s most recent SEC filing?
Acumen Pharmaceuticals, Inc. (ABOS)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-12.
What is ABOS's market cap?
Acumen Pharmaceuticals, Inc. (ABOS) has a market capitalization of $192.91M as of 2026-06-30.
What is ABOS's EPS (earnings per share)?
Acumen Pharmaceuticals, Inc. (ABOS)'s trailing twelve month EPS is $-1.45 as of 2026-06-30.
What is ABOS's ROE (return on equity)?
Acumen Pharmaceuticals, Inc. (ABOS)'s trailing twelve month Return on Equity (ROE) is -120.50% as of 2026-06-30.
What is ABOS's ROA (return on assets)?
Acumen Pharmaceuticals, Inc. (ABOS)'s trailing twelve month Return on Assets (ROA) is -72.97% as of 2026-06-30.
What is ABOS's ROIC (return on invested capital)?
Acumen Pharmaceuticals, Inc. (ABOS)'s trailing twelve month Return on Invested Capital (ROIC) is -151.60% as of 2026-06-30.
What is ABOS's EV/EBITDA?
Acumen Pharmaceuticals, Inc. (ABOS)'s trailing twelve month EV/EBITDA is -1.56x as of 2026-06-30.